Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Jazz Pharmaceuticals' (JAZZ) Weak 4Q Results and 2016 Guidance Has Mizuho Securities Sidelined - PT to $124
February 24, 2016 6:54 AM ESTMizuho Securities reiterated a Neutral rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $124.00 (from $140.00), following the company's 4Q earnings report. JAZZ reported revenue of $340.9M and EPS of $2.60 versus consensus estimates of $350.8M and $2.60. Management also issued below-consensus 2016 guidance of... More
Jazz Pharmaceuticals (JAZZ) Reports In-Line Q4 EPS, FY Guidance Comes in Light
February 23, 2016 4:11 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.60, in-line with the analyst estimate of $2.60. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $349.83 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2016 EPS of $10.90-$11.30, versus the consensus of $11.42. Jazz... More
